National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
5U19AI142790
米国
Other private
GHR Foundation
引用
ジャーナル: Science / 年: 2021 タイトル: Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. 著者: Kathryn M Hastie / Haoyang Li / Daniel Bedinger / Sharon L Schendel / S Moses Dennison / Kan Li / Vamseedhar Rayaprolu / Xiaoying Yu / Colin Mann / Michelle Zandonatti / Ruben Diaz Avalos / ...著者: Kathryn M Hastie / Haoyang Li / Daniel Bedinger / Sharon L Schendel / S Moses Dennison / Kan Li / Vamseedhar Rayaprolu / Xiaoying Yu / Colin Mann / Michelle Zandonatti / Ruben Diaz Avalos / Dawid Zyla / Tierra Buck / Sean Hui / Kelly Shaffer / Chitra Hariharan / Jieyun Yin / Eduardo Olmedillas / Adrian Enriquez / Diptiben Parekh / Milite Abraha / Elizabeth Feeney / Gillian Q Horn / / Yoann Aldon / Hanif Ali / Sanja Aracic / Ronald R Cobb / Ross S Federman / Joseph M Fernandez / Jacob Glanville / Robin Green / Gevorg Grigoryan / Ana G Lujan Hernandez / David D Ho / Kuan-Ying A Huang / John Ingraham / Weidong Jiang / Paul Kellam / Cheolmin Kim / Minsoo Kim / Hyeong Mi Kim / Chao Kong / Shelly J Krebs / Fei Lan / Guojun Lang / Sooyoung Lee / Cheuk Lun Leung / Junli Liu / Yanan Lu / Anna MacCamy / Andrew T McGuire / Anne L Palser / Terence H Rabbitts / Zahra Rikhtegaran Tehrani / Mohammad M Sajadi / Rogier W Sanders / Aaron K Sato / Liang Schweizer / Jimin Seo / Bingqing Shen / Jonne L Snitselaar / Leonidas Stamatatos / Yongcong Tan / Milan T Tomic / Marit J van Gils / Sawsan Youssef / Jian Yu / Tom Z Yuan / Qian Zhang / Bjoern Peters / Georgia D Tomaras / Timothy Germann / Erica Ollmann Saphire / 要旨: Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in ...Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propagated in human-to-human transmission and spillover or spillback events between humans and animals. To develop prevention and therapeutic strategies, we formed an international consortium to map the epitope landscape on the SARS-CoV-2 spike protein, defining and structurally illustrating seven receptor binding domain (RBD)–directed antibody communities with distinct footprints and competition profiles. Pseudovirion-based neutralization assays reveal spike mutations, individually and clustered together in variants, that affect antibody function among the communities. Key classes of RBD-targeted antibodies maintain neutralization activity against these emerging SARS-CoV-2 variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.